Clinical trials: CHF - Congestive Heart Failure
Heart Failure, Congestive
A Study of Iron Oligosaccharide in CHF Patients
The purpose of this study is to determine the safety profile of iron oligosaccharide in patients with congestive heart failure with a need for parenteral iron.
- Trial name
- NCT00537186
- Testing
- Iron oligosaccharide
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Pharmacosmos A/S
Heart Failure, Congestive
PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00328692
- Testing
- rolofylline
- Volunteers
- 932 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cardiovascular Diseases, Congestive Heart Failure
Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
Heart failure is the primary cause of morbidity and mortality worldwide. Currently drug treatments for heart failure manage the symptoms, but not restore the loss cardiomyocytes due to the very limited regenerative capability in…
- Conditions
- Cardiovascular Diseases, Congestive Heart Failure, Dilated Cardiomyopathy
- Trial name
- NCT04982081
- Testing
- hiPSC-CM therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Renal Insufficiency, Congestive Heart Failure
Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency
The purpose of the current study is to assess the safety and tolerability of intravenous tonapofylline.
- Trial name
- TRIDENT-1 (NCT00709865)
- Testing
- tonapofylline
- Where
- 189 sites in United States, Argentina and 16 more
- Volunteers
- 420 people
- Sponsor
- Biogen
Heart Failure, Congestive Heart Failure
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and…
- Trial name
- NECTAR-HF (NCT01385176)
- Testing
- Implant of investigational device system, Titration during the randomization phase, Titration after the randomization phase
- Where
- 21 sites in Belgium, Czechia and 6 more
- Volunteers
- 118 people
- Sponsor
- Boston Scientific Corporation
Heart Failure, Congestive
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are…
- Trial name
- NCT00159627
- Testing
- KW-3902IV
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Congestive Heart Failure
EarlySense Monitoring Device Evaluation on CHF Patients
CHF patients will be monitored using EarlySense ES-16 device and will simultaneously fill diaries and log their weight daily. The data collected and analyzed by the ES-16 device will be correlated with the CHF status data.
- Trial name
- NCT00382746
- Testing
- EarlySense monitoring device
- Where
- Israel
- Sponsor
- EarlySense Ltd.
Acute Heart Failure
A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE 2 (NCT01067859)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 30 sites in United States, Argentina and 7 more
- Volunteers
- 5 people
- Sponsor
- Bayer
Heart Failure, Congestive, Heart Decompensation
Registry for Acute Decompensated Heart Failure Patients Admitted to the ER
The purpose of this study is to collect data on the medical management of patients presenting to the Emergency Department who are treated for Acute Decompensated Heart Failure (ADHF) in a hospital setting that has incorporated a…
- Trial name
- NCT00364325
- Testing
- Acute Decompensated Heart Failure
- Volunteers
- 18,920 people
- Sponsor
- Scios, Inc.
Myocardial Infarction
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.
- Trial name
- ALLSTAR (NCT01458405)
- Testing
- CAP-1002 Allogeneic Cardiosphere-Derived Cells
- Where
- 32 sites in United States
- Volunteers
- 135 people
- Sponsor
- Capricor Inc.
Congestive Heart Failure, Ischemic Cardiomyopathy
Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity
The purpose of the present prospective, randomized study is to investigate the clinical effectiveness of standardized left ventricular reconstruction surgery (LVR).
- Conditions
- Congestive Heart Failure, Ischemic Cardiomyopathy, Coronary Artery Disease, Myocardial Diseases
- Trial name
- NCT00326690
- Testing
- Blue Egg Device
- Where
- 10 sites in United States, Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- BioVentrix
Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system…
- Trial name
- NEUTRALIZE-CRS (NCT03836482)
- Testing
- Selective Cytopheretic Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SeaStar Medical
Congestive Heart Failure
Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667
The purpose of this study is to assess a dose titration scheme, of a new drug (BAY58-2667) given intravenously, to evaluate if this is safe and can help to improve the well-being, symptoms (e.g.
- Trial name
- NCT00559650
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 72 sites in United States, Canada and 15 more
- Volunteers
- 150 people
- Sponsor
- Bayer
Cardiac Failure, Myocardial Failure
An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic
The purpose of this study is to investigate continuous 8-hour introductions of BMS-986231 in participants with heart failure and weakened heart function given a standard dose of diuretic.
- Conditions
- Cardiac Failure, Myocardial Failure, Congestive Heart Failure, Heart Decompensation
- Trial name
- NCT03730961
- Testing
- BMS-986231, Furosemide
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Congestive Heart Failure
Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.
Torasemide is a loop diuretic (pyridine-sulfonylurea)with a wide experience in the treatment of oedema associated to heart failure, kidney or liver disease and either in the treatment of arterial hypertension (alone or combined…
- Trial name
- TORAFIC (NCT00409942)
- Testing
- Torasemide Prolonged Release, Furosemide
- Where
- 23 sites in Spain
- Volunteers
- 142 people
- Sponsor
- Ferrer Internacional S.A.
Heart Failure, Congestive, Dilated Cardiomyopathy
Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
The study is divided into 2 parts. In the first part, the safety of the gene transfer agent MYDICAR® will be evaluated. In the second part, the ability of MYDICAR® to improve heart function will be studied.
- Trial name
- CUPID (NCT00454818)
- Testing
- MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)
- Where
- 22 sites in United States
- Volunteers
- 51 people
- Sponsor
- Celladon Corporation
Congestive Heart Failure
Interventricular Delay of Lumax HF-T for Heart Failure
The purpose of this study is to demonstrate that the safety and efficacy of the Lumax HF-T with optimized interventricular delay biventricular pacing (OPT) is non-inferior to the Lumax HF-T with simultaneous biventricular pacing…
- Trial name
- NCT00508391
- Testing
- Optimized interventricular delay biventricular pacing
- Where
- 19 sites in United States, Switzerland
- Volunteers
- 122 people
- Sponsor
- Biotronik, Inc.
Healthy Participants
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants
The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986308 compared to placebo in healthy participants.
- Trial name
- NCT04763226
- Testing
- BMS-986308, Furosemide
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Heart Failure，Congestive
Comprehensive Medication Monitoring on Heart Failure Patient Outcomes
The purpose of this study is to evaluate the clinical utility of comprehensive medication monitoring using the Patient Medication Profile to improve heart failure patient medication therapy and associated outcomes relative to…
- Trial name
- NCT03519477
- Testing
- Sano Patient Medication Profile
- Where
- United States
- Sponsor
- Precera Bioscience, Inc.
Hypertension, Congestive Heart Failure
To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
To compare and evaluate the efficacy and safety of Candemore tab. versus Atacand tab. on blood pressure in patients with hypertension diagnosed congestive heart failure
- Trial name
- CANTABILE (NCT01682564)
- Testing
- Candemore tablet, Atacand tablet
- Where
- 14 sites in South Korea
- Volunteers
- 169 people
- Sponsor
- Chong Kun Dang Pharmaceutical